Here, we sought to design a macrophage-selective treatment with a low dose of GW1929 PPARγ agonist linked to carbon-based nanoparticles (DGNS-GW) as drug delivery systems for the treatment of liver fibrosis. Here, PPARG is linked to Hepatic fibrosis.